These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31950924)

  • 21. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
    Kaplan SA; Herschorn S; McVary KT; Staskin D; Chapple C; Foley S; Cambronero Santos J; Kristy RM; Choudhury N; Hairston J; Schermer CR
    J Urol; 2020 Jun; 203(6):1163-1171. PubMed ID: 31895002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials.
    Wu Y; Li G; Zhou H; Wu A; Tan G; Huang S; Chen G; Chen X; Li Z
    Urol Int; 2024; 108(2):118-127. PubMed ID: 38185112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Vecchioli Scaldazza C; Morosetti C
    Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial study on effectiveness between tadalafil versus combination mirabegron and solifenacin on treatment of ureteral stent-related symptoms.
    Ciayadi TA; Palinrungi MA; Kholis K; Hendarto J; Syahrir S; Syarif S; Azis A
    Pan Afr Med J; 2023; 46():2. PubMed ID: 37928219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Two Different Drugs for Overactive Bladder, Solifenacin and Mirabegron: A Prospective Randomized Crossover Study.
    Inoue M; Yokoyama T
    Acta Med Okayama; 2019 Oct; 73(5):387-392. PubMed ID: 31649364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY).
    Abrams P; Kelleher C; Staskin D; Kay R; Martan A; Mincik I; Newgreen D; Ridder A; Paireddy A; van Maanen R
    World J Urol; 2017 May; 35(5):827-838. PubMed ID: 27514371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
    Brucker BM; Jericevic D; Rude T; Enemchukwu E; Pape D; Rosenblum N; Charlson ER; Zhovtis-Ryerson L; Howard J; Krupp L; Peyronnet B
    Urology; 2020 Nov; 145():94-99. PubMed ID: 32822687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms.
    El-Nahas AR; Tharwat M; Elsaadany M; Mosbah A; Gaballah MA
    World J Urol; 2016 Jul; 34(7):963-8. PubMed ID: 26453222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamsulosin Monotherapy Is Effective in Reducing Ureteral Stent-related Symptoms: A Meta-analysis of Randomized Controlled Studies.
    Chen YB; Gao L; Jiang Q; Ran K; Luo RT
    Curr Med Sci; 2019 Oct; 39(5):707-718. PubMed ID: 31612387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
    J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial.
    Hsiao SM; Tu FC; Su TC; Wu PC; Lin HH
    Sci Rep; 2022 Aug; 12(1):14219. PubMed ID: 35987885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
    Katoh T; Igawa Y; Yamaguchi O; Kato D; Hamada T; Kuroishi K
    Low Urin Tract Symptoms; 2020 Jan; 12(1):68-80. PubMed ID: 31571403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comprehensive pharmacologic management of overactive bladder].
    Krivoborodov GG; Tur EI
    Urologiia; 2017 Apr; (1):82-88. PubMed ID: 28394529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.